We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
ClinicalTrials.gov Menu

Pilot Study of Hemospan® in Patients With Chronic Critical Limb Ischemia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00633659
Recruitment Status : Completed
First Posted : March 12, 2008
Last Update Posted : August 19, 2013
Information provided by (Responsible Party):

Brief Summary:
The purpose of this study is to evaluate the effects of Hemospan infusion on vascular reactivity, regional perfusion and oxygenation of ischemic tissue in patients with chronic critical lower limb ischemia.

Condition or disease Intervention/treatment Phase
Vascular Disease Critical Lower Limb Ischemia Drug: Hemospan (MP4OX) Drug: Voluven (HES 130/0.4) Phase 2

Detailed Description:

Hemospan® is a novel hemoglobin-based oxygen carrier developed to perfuse and oxygenate tissue at risk for ischemia and hypoxia. Because of its molecular size and oxygen binding characteristics, Hemospan selectively off-loads oxygen in tissues predisposed to low oxygen tension. Preclinical evidence suggests that Hemospan provides volume expansion and enhances tissue perfusion. Hemospan is therefore being developed as an oxygen-carrying plasma expander for patients where tissues are at risk of inadequate perfusion and oxygenation.

In patients with chronic critical lower limb ischemia (CCLI), the primary cause of ischemic symptoms in the leg is insufficient perfusion. As many of the patients suffering from CCLI are elderly and have concomitant disease, surgical procedures may not always be possible. The goal of all treatments is to improve the blood flow in the nutritional vessels of the ischemic areas; one such possibility may be to use an oxygen-carrying plasma expander.

Hemospan has been shown to improve the oxygenation of tissues by preserving functional capillary density. In addition, Hemospan has a high affinity for oxygen - a feature that is specifically designed to target the unloading of oxygen in the microcirculation where local PO2 levels are much lower (e.g., in ischemic regions). Since Hemospan is a cell-free oxygen carrier, it should be able to perfuse capillaries that are so constricted that red blood cells are unable to flow through them.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 6 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single (Participant)
Primary Purpose: Treatment
Official Title: A Phase II Study of Hemospan® Versus Voluven® to Evaluate Vascular Resistance and Forearm Blood Flow, and to Assess Local Skin Blood Flow and Tissue Oxygenation in the Ischemic Foot of Patients With Chronic Critical Limb Ischemia
Study Start Date : September 2007
Actual Primary Completion Date : June 2008
Actual Study Completion Date : December 2008

Resource links provided by the National Library of Medicine

Drug Information available for: Hextend

Arm Intervention/treatment
Experimental: Hemospan (MP4OX)
4.3 g/dL MalPEG-Hb solution
Drug: Hemospan (MP4OX)
250 mL of Hemospan (MP4OX)
Other Names:
  • MP4OX solution
  • 4.3 g/dL MalPEG-Hb
  • PEGylated Hb

Experimental: Control
Voluven (HES 130/0.4)
Drug: Voluven (HES 130/0.4)
250 mL of Voluven (HES 130/0.4) solution
Other Names:
  • 6% hetastarch solution
  • 6% HES 130/0.4

Primary Outcome Measures :
  1. To investigate the effect of Hemospan on vascular resistance by evaluating blood flow in the forearm [ Time Frame: 4 hours ]

Secondary Outcome Measures :
  1. To evaluate the effects of Hemospan on local skin blood flow and tissue oxygenation in an ischemic region of the foot [ Time Frame: 4 hours ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   Child, Adult, Older Adult
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adult male or female (surgically sterile or post-menopausal) patients with CCLI that meet the following definition: i) History of pain at rest and/or ulceration; ii) Ankle systolic BP/Brachial systolic BP Index (ABI) <0.6 at the time of inclusion; iii) Ankle systolic BP <70 mmHg and/or toe systolic BP <50 mmHg
  • Has received written and verbal information about the investigational product and the protocol by the investigator and has had the opportunity to ask questions about the study
  • Patients must sign an Informed Consent Form (ICF), that has been reviewed and approved by the independent Ethics Committee (EC)

Exclusion Criteria:

  • Severe congestive heart failure (EF <40%, or New York Heart Association Class III or IV
  • Any acute or chronic condition that will limit the patient's ability to complete the study
  • Recent acute coronary syndrome (unstable angina or myocardial infarction [MI] within 1 month)
  • Severe dementia or clinically significant psychiatric disorder requiring active treatment
  • Evidence of untreated or uncontrolled hypertension (SBP >180 mmHg, or DBP >100 mmHg), or a difference in systolic BP in each arm that is >15 mmHg (measured by cuff and a pen-Doppler at screening in the supine position, in both arms)
  • Smoking or use of any nicotine-containing product (e.g., snuff) within previous 24 hours before start of study
  • Any systemic rheumatic disease
  • Taking oral steroid therapy (does not include steroids taken intermittently via inhaler)
  • Chronic hepatic disease (abnormal LFTs >3X upper limit of normal, known history of Hepatitis C or B)
  • Chronic renal disease (creatinine >1.8 mg/dL, or known polycystic kidney disease)
  • Expectation of poor patient compliance with study protocol
  • Patients scheduled for surgical procedure within 7 days from start of this study
  • Involved in any investigational drug or device trial within 30 days prior to this study
  • Professional or ancillary personnel involved with this study

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00633659

Layout table for location information
Karolinska Universitetssjukhuset
Stockholm, Sweden
Sponsors and Collaborators
Layout table for investigator information
Principal Investigator: Pär Olofsson, MD, PhD Karolinska University Hospital
Additional Information:
Layout table for additonal information
Responsible Party: Sangart
ClinicalTrials.gov Identifier: NCT00633659    
Other Study ID Numbers: 6034
First Posted: March 12, 2008    Key Record Dates
Last Update Posted: August 19, 2013
Last Verified: August 2013
Keywords provided by Sangart:
Oxygen carriers
Blood substitutes
Tissue oxygenation
Additional relevant MeSH terms:
Layout table for MeSH terms
Vascular Diseases
Pathologic Processes
Cardiovascular Diseases
Hydroxyethyl Starch Derivatives
Pharmaceutical Solutions
Plasma Substitutes
Blood Substitutes